The Goldman Sachs Group Lowers HealthEquity (NASDAQ:HQY) Price Target to $94.00

HealthEquity (NASDAQ:HQY) had its price target dropped by equities research analysts at The Goldman Sachs Group from $107.00 to $94.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 4.75% from the company’s previous close.

Several other research firms have also commented on HQY. Royal Bank of Canada upped their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. KeyCorp lowered their price objective on HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Monday. Mizuho started coverage on HealthEquity in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 target price on the stock. Wells Fargo & Company upped their price target on shares of HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $112.00 price objective on shares of HealthEquity in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, HealthEquity presently has an average rating of “Buy” and a consensus price target of $112.23.

HealthEquity Stock Performance

Shares of HealthEquity stock traded up $0.52 during trading hours on Thursday, reaching $89.74. The company’s stock had a trading volume of 509,058 shares, compared to its average volume of 705,358. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity has a one year low of $65.01 and a one year high of $115.59. The company’s 50 day simple moving average is $104.17 and its 200 day simple moving average is $95.89. The stock has a market cap of $7.76 billion, a P/E ratio of 82.32, a price-to-earnings-growth ratio of 1.60 and a beta of 0.62.

Insider Buying and Selling at HealthEquity

In related news, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the completion of the transaction, the director now owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its position in HealthEquity by 1.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,061,807 shares of the company’s stock worth $86,909,000 after acquiring an additional 14,532 shares during the period. Raymond James Trust N.A. increased its holdings in shares of HealthEquity by 4.8% during the 3rd quarter. Raymond James Trust N.A. now owns 2,905 shares of the company’s stock worth $238,000 after purchasing an additional 132 shares during the period. Citigroup Inc. raised its position in shares of HealthEquity by 73.0% during the third quarter. Citigroup Inc. now owns 102,107 shares of the company’s stock valued at $8,357,000 after buying an additional 43,084 shares during the last quarter. Cerity Partners LLC raised its position in shares of HealthEquity by 15.1% during the third quarter. Cerity Partners LLC now owns 17,259 shares of the company’s stock valued at $1,413,000 after buying an additional 2,258 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of HealthEquity by 165.7% in the third quarter. BNP Paribas Financial Markets now owns 20,437 shares of the company’s stock valued at $1,673,000 after buying an additional 12,745 shares during the period. 99.55% of the stock is owned by institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.